This startup CEO swiftly gained $260M and a dream team of biotech backers — on both sides of the Pacific
Over the course of the past year, it’s become clear that certain elite networks of people in the broader biotech world are able to accomplish big things almost overnight.
Zhi Hong, a longtime infectious disease research expert at GlaxoSmithKline, just found out for himself how big.
Since the end of February, leaving GSK after an 11-year stretch, he’s gained commitments of $260 million — it’s tranched — from some of the top biotech investors on both sides of the Pacific for a new company dubbed Brii Bio that plans to in-license a pipeline of drugs out of the US. And he’s starting out with an ultra-connected industry startup in the US for a biotech partner.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
